Artiva Biotherapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Artiva Biotherapeutics, Inc. carries a market capitalization of 547.08M, placing it among publicly traded companies globally. Its enterprise value stands at 134.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 547.08M |
| Enterprise Value | 134.65M |
Share Statistics
Artiva Biotherapeutics, Inc. currently has 48.89M shares outstanding.
| Shares Outstanding | 48.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | -3.89 |
| P/OCF Ratio | -3.81 |
Financial Position
Artiva Biotherapeutics, Inc. maintains a current ratio of 24.16, meaning it holds 24.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 24.16 |
| Quick Ratio | 23.97 |
| Debt / Equity | 2.83 |
| Debt / EBITDA | -0.11 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -36.58 |
| Return on Assets (ROA) | -33.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Artiva Biotherapeutics, Inc.'s stock has gained approximately 259.80707% over the past 52 weeks. The 50-day moving average sits at 10.52, while the 200-day moving average is 7.37.
| Beta (5Y) | N/A |
| 52-Week Price Change | 259.80707% |
| 50-Day Moving Average | 10.52 |
| 200-Day Moving Average | 7.37 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -93.46M, while operating income came in at -96.15M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -96.15M |
| Pretax Income | -90.82M |
| Net Income | -90.82M |
| EBITDA | -93.46M |
| EBIT | -96.15M |
| Earnings Per Share (EPS) | -3.08 |
Balance Sheet
Artiva Biotherapeutics, Inc. holds 349.39M in cash and equivalents against 9.85M in total debt, resulting in a net debt position of -301.45M. Total book value stands at 347.50M, with working capital of 337.70M providing operational flexibility.
| Cash & Cash Equivalents | 349.39M |
| Total Debt | 9.85M |
| Net Debt | -301.45M |
| Equity (Book Value) | 347.50M |
| Book Value Per Share | 7.11 |
| Working Capital | 337.70M |
Cash Flow
Artiva Biotherapeutics, Inc. produced -75.23M in operating cash flow over the past twelve months. After subtracting -1.68M in capital expenditures, free cash flow totaled -76.91M - equivalent to -2.60 per share.
| Operating Cash Flow | -75.23M |
| Capital Expenditures | -1.68M |
| Free Cash Flow | -76.91M |
| FCF Per Share | -2.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -59.68 |
| FCF Yield | -25.68 |
Scores
Artiva Biotherapeutics, Inc. posts an Altman Z-Score of 12.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 12.26 |